ストックスクリーナーアプリを入手
6.95
3.40%
0.21
アフターアワーズ：
7.19
0.24
+3.45%
Vir Biotechnology Inc (VIR) 最新ニュース
Needham & Company LLC Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Empowered Funds LLC Decreases Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - BioSpace
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BioSpace
VIRVir Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial | VIR Stock News - StockTitan
EMA grants orphan drug status to Vir Biotech hepatitis treatments - Investing.com
EMA grants orphan drug status to Vir Biotech hepatitis treatments By Investing.com - Investing.com Canada
Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - StreetInsider.com
Vir Biotechnology Secures Key EU Orphan Drug Status for Hepatitis Delta Treatment | VIR Stock News - StockTitan
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat
(VIR) Proactive Strategies - Stock Traders Daily
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance
Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com
Vir Biotechnology Inc. (VIR) Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations - StreetInsider.com
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire
Baillie Gifford & Co. Reduces Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology's EVP sells shares worth $44,453 - Investing.com India
Vir Biotechnology's EVP sells shares worth $44,453 By Investing.com - Investing.com UK
Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares - Investing.com India
Leerink Partnrs Has Negative Outlook of VIR FY2024 Earnings - MarketBeat
HC Wainwright Expects Lower Earnings for Vir Biotechnology - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript - MSN
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off (NASDAQ:VIR) - Seeking Alpha
VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges - Investing.com India
VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com Nigeria
Trading (VIR) With Integrated Risk Controls - Stock Traders Daily
HC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Price Target Cut to $26.00 by Analysts at Barclays - MarketBeat
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Finance
Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada
Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Misses Estimates By $0.51 EPS - MarketBeat
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Vir Biotechnology Q3 2024 Earnings Preview - MSN
Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials By Investing.com - Investing.com South Africa
Stock Traders Buy High Volume of Call Options on Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials - Investing.com
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down on Disappointing Earnings - MarketBeat
Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - MarketBeat
Vir Biotechnology Reports Q3 2024 Financial Results - TipRanks
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - BioSpace
Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 51c - StreetInsider.com
Trend Tracker for (VIR) - Stock Traders Daily
Vir Biotechnology (VIR) to Release Earnings on Thursday - MarketBeat
State Street Corp's Strategic Acquisition in Vir Biotechnology Inc - Yahoo Finance
State Street Corp's Strategic Acquisition in Vir Biotechnology I - GuruFocus.com
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 - BioSpace
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):